信立泰：泰卡西单抗注射液申报上市申请获受理

Core Viewpoint - The company, Xinlitai (002294.SZ), has announced that its subsidiary, Xinlitai (Suzhou) Pharmaceutical Co., Ltd., has received acceptance for the market application of its self-developed Class 1 biological drug, "Taikasi Monoclonal Antibody Injection," from the National Medical Products Administration. The intended indications for this drug are hypercholesterolemia and mixed dyslipidemia [1]. Summary by Categories Company Developments - Xinlitai has successfully submitted a market application for its new biological drug, indicating progress in its research and development efforts [1]. Product Information - The drug "Taikasi Monoclonal Antibody Injection" targets high cholesterol levels and mixed lipid disorders, which are significant health concerns [1].